2023
DOI: 10.3389/fneur.2023.1228098
|View full text |Cite
|
Sign up to set email alerts
|

Botulinum toxin type A for genitofemoral neuralgia: A case report

Abstract: Genitofemoral neuralgia is an uncommon pain disorder that could be resistant to conventional treatment. A 78-year-old woman with refractory right genitofemoral neuralgia was treated with BoNT/A subcutaneous injections; the treatment was performed three times with significant pain improvement, although temporary, and without adverse events. BoNT/A may be a promising alternative intervention in the setting of genitofemoral neuralgia refractory to oral and/or topical treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
(58 reference statements)
0
1
0
Order By: Relevance
“…The initial treatment of inguinal neuralgia is based on the use of nonsteroidal anti-inflammatory drugs and medicines for neuropathic pain [3] . In addition, chronic pain in GF neuralgia can be treated by various methods, including steroid injections, nerve stimulators, neurectomy, pain stimulators, nerve blocks, and botulinum toxin [7] , [8] , [9] . Forms that are resistant to analgesic treatment and require invasive methods to manage the pain syndrome should be re-evaluated, as demonstrated in this study.…”
Section: Discussionmentioning
confidence: 99%
“…The initial treatment of inguinal neuralgia is based on the use of nonsteroidal anti-inflammatory drugs and medicines for neuropathic pain [3] . In addition, chronic pain in GF neuralgia can be treated by various methods, including steroid injections, nerve stimulators, neurectomy, pain stimulators, nerve blocks, and botulinum toxin [7] , [8] , [9] . Forms that are resistant to analgesic treatment and require invasive methods to manage the pain syndrome should be re-evaluated, as demonstrated in this study.…”
Section: Discussionmentioning
confidence: 99%